Harmony had a profitable commercial product and resources to invest in its future. The central uncertainty was whether it could preserve the economics of WAKIX while building additional approved products. Reformulation, patents and new clinical programs were possible routes to that outcome; none was a completed substitute for the existing franchise.

Growth was strong, but margins did not expand

In Q3 2025, net product revenue reached $239.5 million, compared with $186.0 million a year earlier. Average patients were approximately 8,100. Harmony reported $778.4 million of cash, cash equivalents and investments. GAAP diluted EPS was $0.87; adjusted EPS was $1.08. These are the figures in its November results.

Operating income rose from $61.710 million to $65.487 million. Dividing by revenue gives an operating margin of about 27.3%, down from 33.2%. Revenue growth therefore did not translate into widening operating margin that quarter. Higher investment can be justified, but it should be recognized as investment requiring a future return.

The balance sheet gave Harmony more flexibility than a company dependent on frequent new share issuance. It did not guarantee that every pipeline program or acquisition could be funded indefinitely without cost to shareholders. Cash is a resource to allocate, not evidence that development risk has disappeared.

What pitolisant GR established

Harmony’s November 24 announcement reported bioequivalence between 17.8mg pitolisant GR and existing WAKIX. The exposure ratios were 108.46% for AUC and 99.65% for Cmax; the corresponding 90% confidence intervals were 103.74–113.41% and 91.95–108.00%. The company planned an NDA in early 2026 and described patent applications with potential protection to 2044.

Bioequivalence supports comparability of drug exposure. It does not, by itself, demonstrate fewer gastrointestinal symptoms, better long-term retention or greater efficacy. A study in which participants can start at a therapeutic dose also should not be converted into a promise that all patients will benefit sooner.

A new patent is not protection for every version of the drug

The commercial importance of a reformulation depends on several separate steps: regulatory approval, enforceable patent claims, a meaningful patient benefit and a reason for patients and payers to prefer it. Patent protection for a new formulation does not automatically prevent competition with the older formulation.

This creates a useful boundary case. GR could obtain approval and relevant patents, yet the original tablets could face lower-priced alternatives. If patients do not switch or coverage is restrictive, the new formulation may preserve less revenue than its nominal patent life suggests. An investment case must model adoption rather than equating “2044” with an annuity.

Pipeline breadth is different from revenue diversification

The 2025 development plan included high-dose pitolisant, an orexin-2 receptor agonist and epilepsy programs. These provided possible routes beyond the current product. Until they produced successful trials, approvals and sales, the commercial concentration remained.

WAKIX’s established label in the reviewed period covered specified narcolepsy uses; it did not establish an approved idiopathic-hypersomnia treatment. Its non-controlled status also should not be used as shorthand for an absence of safety issues: the prescribing information includes QT-prolongation precautions.

Preclinical potency of an orexin candidate is an early research observation, not proof of superior clinical efficacy or protection against liver toxicity. A lower dose in milligrams is not inherently safer across different molecules. Likewise, results from separate competitor trials cannot establish a head-to-head ranking without comparable populations and methods.

Harmony’s November results stated that the failed ZYN002 trial was under further review and that the 22q program was paused. That was more limited than saying the entire development decision had been finalized.

The investment test

The persuasive case for Harmony was the combination of real product demand and the capacity to fund development. The unresolved question was the return on that spending as competition and generic exposure evolved. The next evidence to look for was a viable regulatory package, defensible product differentiation and sustainable cash generation after research costs. Analyst targets and institutional ownership could not substitute for those tests.

The BioCryst portfolio case offers a related example of why pipeline breadth and approved revenue diversification are different measures.